Hereditary Amyloidosis Treatment Market
Hereditary Amyloidosis Treatment Market Scope:
Industry Analysis, Market Size, Growth, Trends Till
2031
Request Sample Report
Hereditary Amyloidosis Treatment Market Size and Growth
The Hereditary Amyloidosis Treatment market is growing due to increasing awareness, advancements in therapies, and a rising patient population. The market size was valued at approximately USD 1.2 billion in 2023, with projections indicating continued growth driven by innovative treatment options and expanding clinical trials exploring new therapeutic approaches.
Sample Report
Companies Covered
(Covid 19 Impact Covered)
◍ Baxter
◍ Johnson & Johnson
◍ Alnylam Pharmaceuticals
◍ Pfizer
◍ Prothena
◍ GlaxoSmithKline
◍ Ionis Pharmaceuticals
◍ BridgeBio Pharma
◍ SOM Innovation Biotech
The hereditary amyloidosis treatment market features key players like Baxter, Johnson & Johnson, Alnylam Pharmaceuticals, Pfizer, Prothena, GlaxoSmithKline, Ionis Pharmaceuticals, BridgeBio Pharma, and SOM Innovation Biotech. These companies innovate therapies, drive clinical trials, and expand access, contributing significantly to market growth.
Sales revenue highlights include:
- Alnylam Pharmaceuticals: ~$750 million (2022)
- Pfizer: ~$81.29 billion (2022)
- GSK: ~$42.43 billion (2022)
Request Sample Report
Market Segmentation
By Application
Hospitals
Clinics
Others
Request Sample Report
By Product
Drug Treatment
Surgical Treatment
Market Growth
Request Sample Report
$ 0.21 Billion
